A Prospective 3-Year Follow-up Study in Subjects Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2017
At a glance
- Drugs AL 335/odalasvir/simeprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 20 Jun 2017 Planned End Date changed from 6 Dec 2021 to 7 Jan 2022.
- 12 Apr 2017 Status changed from not yet recruiting to recruiting.
- 07 Apr 2017 New trial record